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INTRODUCTION
The intestinal epithelium is highly dynamic, 
undergoing continuous cycles of renewal and repair. Stem 
cells at the base of crypts give rise to progenitor cells that 
continue to divide, migrate up the crypt-villus axis, and 
differentiate into the specialized epithelial cell types of 
the intestine [1]. Absorptive cells are sloughed off into the 
intestinal lumen in a conveyor belt fashion on a weekly 
basis, while secretory cells such as tuft cells and Paneth 
cells survive for weeks [2, 3]. Beyond this programmed 
turnover, intestinal insults, such as inflammation, oxidative 
damage, and radiation [4, 5] induce cell death, requiring 
replacement to maintain the epithelial barrier. These 
processes of turnover and regeneration are driven by an 
equally dynamic population of intestinal stem cells (ISCs) 
whose characteristics are only beginning to emerge [2].
The highly organized ISC compartment at the 
base of crypts contains cell types with distinct marker 
expression and functional phenotypes. Lgr5+, or crypt 
base columnar (CBC), cells are long-lived multipotent 
stem cells located at crypt cell positions 0–4 that 
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ABSTRACT
Long-lived multipotent stem cells (ISCs) at the base of intestinal crypts adjust 
their phenotypes to accommodate normal maintenance and post-injury regeneration 
of the epithelium. Their long life, lineage plasticity, and proliferative potential 
underlie the necessity for tight homeostatic regulation of the ISC compartment. 
In that context, the guanylate cyclase C (GUCY2C) receptor and its paracrine 
ligands regulate intestinal epithelial homeostasis, including proliferation, lineage 
commitment, and DNA damage repair. However, a role for this axis in maintaining 
ISCs remains unknown. Transgenic mice enabling analysis of ISCs (Lgr5-GFP) in the 
context of GUCY2C elimination (Gucy2c–/–) were combined with immunodetection 
techniques and pharmacological treatments to define the role of the GUCY2C signaling 
axis in supporting ISCs. ISCs were reduced in Gucy2c–/– mice, associated with loss 
of active Lgr5+ cells but a reciprocal increase in reserve Bmi1+ cells. GUCY2C was 
expressed in crypt base Lgr5+ cells in which it mediates canonical cyclic (c) GMP-
dependent signaling. Endoplasmic reticulum (ER) stress, typically absent from ISCs, 
was elevated throughout the crypt base in Gucy2c–/– mice. The chemical chaperone 
tauroursodeoxycholic acid resolved this ER stress and restored the balance of ISCs, 
an effect mimicked by the GUCY2C effector 8Br-cGMP. Reduced ISCs in Gucy2c–/–mice 
was associated with greater epithelial injury and impaired regeneration following 
sub-lethal doses of irradiation. These observations suggest that GUCY2C provides 
homeostatic signals that modulate ER stress and cell vulnerability as part of the 
machinery contributing to the integrity of ISCs.
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divide daily to drive weekly turnover of the epithelium, 
making them the “active” stem cells [6]. These cells are 
exquisitely sensitive to insult and are intimately associated 
with differentiated cells that supply essential regulatory 
signals, including Paneth cells [6-8]. Another long-lived, 
multipotent stem cell type located higher up the crypt 
axis around cell positions 4–8 commonly expresses the 
marker Bmi1 [9]. These Bmi1+ cells are quiescent and 
contribute minimally to tissue homeostasis [6]. However, 
upon injury, Bmi1+ cells can restore both the more active 
CBCs as well as all of the differentiated cell types of the 
intestinal epithelium, earning them the label of “reserve” 
ISC [6, 10]. Despite the sensitivity of Lgr5+ cells to death 
upon intestinal insult and the contribution of Bmi1+ cells 
to regeneration, Lgr5+ cells are required for recovery from 
radiation-induced gastrointestinal damage [5]. While the 
identity and function of intestinal stem cell populations are 
emerging, mechanisms contributing to their maintenance 
and relative balance continue to be refined [6-8, 11].
GUCY2C is a membrane-associated guanylate 
cyclase receptor selectively expressed in apical membranes 
of intestinal epithelial cells from the duodenum to the 
distal rectum [12]. Cognate ligands are structurally similar 
peptides and include the paracrine hormones guanylin, 
produced throughout the intestine, and uroguanylin, 
produced selectively in small intestine, and the heat-stable 
enterotoxins (STs) produced by diarrheagenic bacteria 
[12]. GUCY2C originally was identified as a mediator of 
intestinal fluid and electrolyte secretion contributing to the 
pathophysiology of enterotoxigenic diarrhea [12]. However, 
the GUCY2C-paracrine hormone axis has emerged as an 
essential regulator of key homeostatic processes, including 
cell proliferation [13, 14], lineage commitment [15], and 
DNA damage repair [14], functions that are essential to 
the integrity of the crypt [16]. Further, in murine models 
of tumorigenesis or inflammatory bowel disease, in which 
injury and recovery characteristically involve ISCs [17], 
silencing GUCY2C amplifies pathophysiology, tissue 
damage, and mortality [14, 18–21]. Here, we explore the 
role for GUCY2C signaling in maintaining ISCs.
RESULTS
Eliminating GUCY2C expression disrupts ISC 
numbers
Stem cells were enumerated in small intestinal 
crypts from Gucy2c+/+ and Gucy2c–/– mice by electron 
microscopy. Wedge-shaped cells in crypt positions 
0 to 5 were included, and Paneth cells were excluded by 
their vesicular morphology (Figure 1A) [6–8]. The total 
number of ISCs in the crypt base was reduced in the absence 
of GUCY2C (Figure 1B). Similarly, ex vivo enteroid 
formation, a measure of ISC number and function [22], 
was reduced in the absence of GUCY2C ( p < 0.001; Figure 
1C). FACS analyses revealed fewer Lgr5+/GFPHigh cells in 
Lgr5-EGFP-IRES-CreERT2 mice in which GUCY2C was 
eliminated (Lgr5-EGFP-Cre-Gucy2c–/–; Supplementary 
Figure 1 and Figure 1D), confirmed by immunofluorescence 
microscopy (Figure 1E–1F and Supplementary Figure 
2). Moreover, lineage tracing in Lgr5-EGFP-Cre-
Gucy2c+/+ and –Gucy2c–/– mice crossed onto the Rosa-
STOPfl-LacZ background revealed that Gucy2c–/– mice 
had fewer LacZ-labeled crypts (Figure 1G–1H). 
Conversely, Gucy2c–/– mice exhibited an expanded 
population of Bmi1+ cells by immunofluorescence 
microscopy (Figure 1I–1J and Supplementary Figure 3) 
which was confirmed by immunoblot analysis (Figure 
1K–1L). Together, these results suggest that eliminating 
GUCY2C signaling rebalances stem cell populations, 
favoring a “reserve” ISC phenotype.
Functional expression of the GUCY2C signaling 
axis in ISCs
Lgr5+GFP+ cells were collected by FACS from 
Lgr5-EGFP-Cre-Gucy2c+/+ and –Gucy2c–/– mice 
(Supplementary Figure 4) [23] and enrichment verified by 
RT-qPCR of stem (Lgr5) and differentiated cell [sucrose 
isomaltase (SI)] mRNA markers (Figure 2A). Expression 
of Gucy2c mRNA in stem (Lgr5High/SILow) cells was 
quantitatively similar to that of differentiated (Lgr5Low/
SIHigh) cells suggesting similar levels of expression in 
stem cell and differentiated compartments (Figure 2B). 
Immunofluorescence microscopy confirmed specific 
co-localization of GUCY2C in Lgr5+GFP+ stem cells 
(Figure 2C and Supplementary Figure 5). To confirm 
functionality of the GUCY2C receptor in ISCs, ST was 
injected into segments of intestinal lumen of Lgr5-EGFP-
Cre-Gucy2c+/+ and Lgr5-EGFP-Cre-Gucy2c–/– mice [24]. 
Luminal exposure to this GUCY2C agonist [25] produced 
cGMP accumulation and cGMP-specific phosphorylation 
of the downstream target of cGMP-dependent protein 
kinase, vasodilator-stimulated phosphoprotein (VASP), in 
Lgr5+GFP+ cells, in Gucy2c+/+, but not in Gucy2c–/–, mice 
(Figure 2D) highlighting the functionality of GUCY2C 
in ISCs. Further, 8Br-cGMP, a cell-permeable analog of 
the GUCY2C second messenger cGMP [26], restored the 
balance of ISCs, returning Lgr5+GFP+ (Figure 2E) and 
Bmi1+ (Figure 2F) cells in Gucy2c–/– mice to levels that 
were comparable to those in Gucy2c+/+ mice. Moreover, 
the oral GUCY2C agonist linaclotide (Linzess™, 
Ironwood, Cambridge, MA) amplified the efficiency of 
enteroid formation in Gucy2c+/+ mice (Figure 2G). These 
observations reinforce the role of GUCY2C signaling in 
maintaining ISCs.
GUCY2C signaling opposes crypt ER stress
The normal ISC compartment minimizes endoplasmic 
reticulum (ER) stress, and prolonged exposure induces 
ISCs to shift from the stem cell compartment into the 
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proliferating progenitor cell pool [27, 28], an effect which 
is phenocopied by eliminating GUCY2C signaling [13–15, 
20, 29]. Here, elimination of GUCY2C expression induced 
over-expression of the chaperone protein BiP (Grp78), a 
canonical marker of ER stress [30], in crypts in Gucy2c–/– 
mice (Figure 3A–3D). Interestingly, markers of the unfolded 
protein response induced by ER stress, including ATF6, 
calreticulin, and phosphorylated eIF2α (p-eIF2α), were 
unchanged in those crypts [31] (Figure 3A, 3B). Moreover, 
the pro-apoptotic protein CHOP, which eliminates cells 
with irreversible ER stress [32], was paradoxically reduced 
in those crypts (Figure 3A, 3B). This pattern of markers 
specifically reflects adaptive ER stress, in which chaperones 
like BiP are over-expressed to relieve chronic ER stress, 
minimizing the unfolded protein response, while CHOP 
transcription is down-regulated to prevent cell death [33, 34]. 
In that context, tauroursodeoxycholic acid (TUDCA), a 
bile salt that mimics the chaperone protein BiP to reduce 
ER stress by relieving protein misfolding [35], restored 
normal BiP expression in crypts in Gucy2c–/– mice, an 
effect which was mimicked by 8Br-cGMP (Figure 3C–3D). 
Moreover, like 8Br-cGMP (Figure 2F–2G), TUDCA also 
restored Lgr5+GFP+ (Figure 3E) and Bmi1+ (Figure 3F) 
cells to normal levels in Gucy2c–/– mice. These observations 
underscore the role of GUCY2C signaling in opposing ER 
stress that is essential to maintaining ISCs.
GUCY2C maintains ISCs supporting 
regeneration after radiation injury
Intestinal irradiation is an established model to 
quantify ISC vulnerability and regenerative capacity [36]. 
Lgr5+ cells are exquisitely sensitive to, and depleted by, 
irradiation while Bmi1+ cells are recruited to expand and 
repopulate the crypt base to support regeneration [6]. A 
single sub-lethal 10 Gy dose of whole-body radiation 
produced massive crypt death quantified by the microcolony 
assay [37] in small intestines of Gucy2c+/+ and Gucy2c–/– 
mice (Figure 4A). However, Gucy2c–/– mice displayed 
greater fractional crypt loss compared to Gucy2c+/+ mice 
48 hours after irradiation (36% vs 62%, p < 0.05), consistent 
with increased susceptibility to radiation-induced ISC cell 
death in the absence of GUCY2C signaling (Figure 4A). 
Further, the absence of GUCY2C signaling was associated 
with a regenerative lag; Gucy2c–/– mice recovered only 
49% of their crypts compared to 82% in Gucy2c+/+ mice at 
72 hours ( p < 0.01), consistent with enhanced vulnerability 
of the crypt in the absence of GUCY2C (Figure 4A–4B). 
Figure 1: Gucy2c maintains the balance of Lgr5+ and Bmi1+ cells in crypts. (A–B) Enumeration of CBC ISCs in small 
intestinal sections using transmission electron microscopy (n = 3 mice, >30 crypts/mouse). (C) Ex vivo enteroid forming capacity of 
crypts from Gucy2c–/– mice relative to Gucy2c+/+ mice. (D) Quantification of Lgr5+ (GFPHigh) cells by flow cytometry in crypts from Lgr5-
EGFP-Cre-Gucy2c+/+ and Gucy2c–/– mice. (E–F) Enumeration of Lgr5+GFP+ cells in intestinal crypts by EGFP IF (>4 sections/mouse). 
(G–H) Crypt Lgr5+ cell lineage tracing events expressed as a percent of total crypts per section (>4 sections/mouse). (I–J) Bmi1+ cells 
per intestinal section (>4 sections/mouse). (K–L) Quantification of Bmi1 expressed in isolated crypt lysates, relative to β-actin (n = 5 
Gucy2c+/+, 4 Gucy2c–/–). *p < 0.05; ***p < 0.001. Bars in E and G represent 50 µm; bar in I represents 20 µm.
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Indeed, the absolute number of Lgr5+GFP+ cells 48 hours 
after irradiation was lower (31 vs 9, p < 0.05) in Gucy2c–/–, 
compared to Gucy2c+/+, mice (Figure 4C). In contrast, 
Bmi1+ cells expanded to repopulate the crypt after radiation 
in Gucy2c+/+ mice, achieving a maximum response at 
48 h, while in Gucy2c–/– mice there was a paradoxical loss 
of those cells, without recovery, (p < 0.01; Figure 4D), 
paralleling the regenerative lag (Figure 4A). Together, 
these observations support the hypothesis that GUCY2C 
signaling, at least in part, protects Lgr5+ and Bmi1+ stem 
cells required for regenerative responses to radiation injury.
DISCUSSION
An emerging paradigm suggests that the crypt 
harbors populations of multi-potent stem cells which 
Figure 2: Functional GUCY2C is expressed in Lgr5+ cells. (A) Flow sorting of GFP+ and GFP– cells from crypts of Lgr5-EGFP-
Cre-Gucy2c+/+ mice produced populations of active stem (Lgr5High/SILow) and differentiated (Lgr5Low/SIHigh) cells (n = 3). (B) GUCY2C mRNA 
expression, quantified by RT-PCR, was compared in Lgr5High/SILow and Lgr5Low/SIHigh cells. (C) GUCY2C (green), immunofluorescence in 
GFP+ (red) cells. β-catenin (cyan) highlights individual cells and DAPI (blue) highlights nuclei. (D) ST activates GUCY2C and downstream 
VASP serine 239 phosphorylation (P-VASP-239) (white) in GFP+ (green) cells in Gucy2c+/+, but not Gucy2c–/–, mice. β-catenin (red) 
highlights individual cells and DAPI (blue) highlights nuclei. (E–F) 8Br-cGMP reconstitutes levels of (E) Lgr5+GFP+ and (F) Bmi1+ cells 
in crypts of Gucy2c–/– mice that are comparable to those in Gucy2c+/+ mice. (G) Linaclotide enhances the enteroid-forming capacity of 
crypts in Gucy2c–/– mice relative to Gucy2c+/+ mice. *p < 0.05; ns, not significant. Bar in C represents 50 µm; bar in D represents 20 µm.
Oncotarget102927www.impactjournals.com/oncotarget
support the unique homeostatic requirements of the 
continuously regenerating intestinal epithelium. 
While several intestinal stem cell populations have 
been suggested, reflecting phenotypic and functional 
characteristics, there is consensus on two broad categories 
[38]. Active crypt base stem cells at position 0-4 which are 
rapidly proliferating and sensitive to insults like radiation 
are the source of transit amplifying cells which ultimately 
replace differentiated epithelial cells in routine mucosal 
maintenance [6, 39]. In contrast, stem cells residing at 
positions above 4, which are slowly proliferating and 
relatively resistant to insults, comprise a reserve population 
that regenerates the intestinal epithelium following injury 
[40]. While several protein markers have been purported 
to identify discreet stem cell populations, all are variably 
expressed by ISCs in crypts [41]. However, Lgr5 and 
Bmi1 appear to be relatively selective as markers of 
active and reserve stem cell populations, respectively [38]. 
This heterogeneity in marker expression likely reflects 
the plasticity of ISCs. Indeed, rather than discreet stable 
populations, ISCs likely transition between active and 
reserve phenotypes to meet the instantaneous needs of 
normal or injured epithelium [42]. This plasticity creates 
functional capacity to accommodate wide variations in 
environmental challenges to the integrity of the mucosa 
[43]. In turn, this plasticity requires specific mechanisms 
that maintain the quantity and relative balance of active 
and reserve stem cells and are only now being discovered.
Here, we reveal that GUCY2C is one key 
determinant of the quantity and relative balance of active 
and reserve ISCs. In the absence of GUCY2C, there is a 
reduction in the quantity of ISCs, reflected in their overall 
number and in their ability to form enteroids ex vivo. Also, 
there is a shift in the relative balance of these cells with 
a decrease in active Lgr5+ cells and a reciprocal increase 
in reserve Bmi1+ cells. Regulation of the quantity and 
Figure 3: GUCY2C opposes ER stress balancing active and reserve ISCs. (A, B) Quantification of crypt ER stress marker 
expression, relative to tubulin, in Gucy2c+/+ and Gucy2c–/– mice (n = 3). (C, D) Grp78 (BiP) expression in crypts (*) of Gucy2c+/+ mice, 
and Gucy2c–/– mice before and after treatment with TUDCA or 8Br-cGMP. (E, F) Quantification of crypt Lgr5+GFP+ and Bmi1+ cells in 
Gucy2c+/+ and Gucy2c–/– mice following oral TUDCA for 3 d. *p < 0.05; ***p < 0.001; ns, not significant. Bar in C represents 20 µm.
Oncotarget102928www.impactjournals.com/oncotarget
relative balance of ISCs is associated with the functional 
co-expression of GUCY2C in stem cells. In that context, 
reconstitution of cGMP signaling by oral delivery of 8Br-
cGMP in Gucy2c–/– mice restored the quantity and relative 
balance of active and reserve stem cells. Eliminating 
GUCY2C is associated with chronic ER stress in crypts, 
a process associated with loss of stem cells in intestine 
[34, 44]. ER stress may contribute to ISC loss in Gucy2c–/– 
mice since 8Br-cGMP or TUDCA, a chemical chaperone 
[35], resolved ER stress and restored the quantity and 
balance of Lgr5+ and Bmi1+ stem cells. Importantly, 
silencing GUCY2C increased ISC vulnerability, stem 
cell loss, and epithelial injury and delayed regeneration in 
Gucy2c–/– mice exposed to sub-lethal doses of radiation. 
These observations highlight a previously unknown role 
for GUCY2C in maintaining and balancing pools of active 
and reserve stem cells which, in turn, impacts regenerative 
epithelial responses to environmental insults.
Mechanisms regulating ISC pools by GUCY2C are 
likely complex and multi-factorial. Generally, GUCY2C 
effects are mediated by luminocentric paracrine and 
autocrine signaling driven by the hormones guanylin and 
uroguanylin [19]. In ISCs, this regulation may be mediated 
selectively by guanylin, whose mRNA is expressed in 
intestinal crypts [45]. The effects of hormone signaling 
may be cell-autonomous, mediated directly by ISCs, 
which express GUCY2C in apical membranes making 
them accessible to luminocentric hormone secretion. 
Alternatively, these effects may be non-autonomous 
reflecting the essential role of Paneth cells in maintaining 
ISCs [2, 8, 23, 36] and the loss of those cells when 
GUCY2C is silenced [14]. Also, loss of ISCs in the 
absence of GUCY2C may reflect the associated ER stress, 
which exits stem cells out of the active Lgr5+ pool and into 
the proliferating progenitor (transit amplifying) pool as 
part of the canonical differentiation program that renews 
the intestinal epithelium [34]. Indeed, these observations 
provide one mechanistic explanation for expansion of the 
proliferating progenitor cell compartment in intestinal 
crypts in Gucy2c–/– mice [13–15, 20, 29]. Further, loss of 
ISCs in the absence of GUCY2C may reflect an increase 
in stem cell vulnerability to environmental insults, again 
likely reflecting the associated chronic ER stress which 
amplifies stem cell susceptibility to apoptosis [44]. In 
that regard, GUCY2C signaling enhances resistance of 
intestinal epithelial cells to chemical, inflammatory and 
radiation-induced injury [14, 18, 21, 46-48]. Moreover, 
here we reveal that active Lgr5+ cells and reserve Bmi1+ 
cells, which are typically resistant to insults [6], are 
sensitized to radiation injury in the absence of GUCY2C 
signaling. Beyond exiting stem cells from the ISC pool 
and amplifying their vulnerability, the impact of GUCY2C 
signaling on the plasticity of ISCs and their ability to shift 
between active and reserve pools remains to be defined. 
In that context, while there is a reciprocal increase in the 
reserve Bmi1+ cell pool in Gucy2c–/– mice, these cells fail 
to fully compensate for the loss of, or restore, active Lgr5+ 
cells in the normal or irradiated epithelium, respectively. 
These observations suggest that GUCY2C signaling may 
play a role in the interconversion of Bmi1+ and Lgr5+ cells 
that, in part, defines the functional capacity to regenerate 
in response to environmental insults.
Based on the present observations, it is tempting 
to speculate that the role of GUCY2C signaling in 
pathophysiological mechanisms reflects, at least in part, 
a contribution of dysregulation of the ISC compartment. 
Figure 4: Maintenance of ISCs by GUCY2C contributes to regenerative responses following radiation-induced intestinal 
injury. Lgr5-EGFP-Cre-Gucy2c+/+ and –Gucy2c–/– mice received 10 Gy of irradiation and the dynamics of (A–B) viable crypts, (C) GFP+Lgr5+ 
active stem cells, and (D) Bmi1+ reserve stem cells were quantified over the subsequent 3 days. Bar in B represents 100 µm.
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The GUCY2C signaling axis is universally silenced in 
colorectal cancer reflecting loss of expression of guanylin 
in transforming crypts [49-51]. Conversely, eliminating 
GUCY2C expression promotes intestinal tumorigenesis 
[14, 20, 52]. The current pathophysiological paradigm of 
intestinal cancer suggests that initiating transformational 
events occur in the stem cell compartment [53]. Further, 
Bmi1 has been identified as an important transcription 
factor supporting the transformation of cancer stem cells 
in a variety of tumors [54, 55]. Moreover, GUCY2C is a 
key component of mechanisms regulating DNA damage 
repair [14]. These observations suggest a hypothesis in 
which loss of guanylin silences GUCY2C, shifting ISC 
pools from active Lgr5+ cells to Bmi1+ cells which, in 
the absence of cGMP signaling, may be particularly 
vulnerable to genotoxic insults amplifying the risk of 
transformation and cancer. Similarly, inflammatory bowel 
disease (IBD) is associated with a loss of components of 
the GUCY2C signaling axis [56]. Conversely, eliminating 
GUCY2C signaling amplifies tissue injury and mortality in 
rodent models of IBD [18, 21, 47, 48]. These data suggest 
a hypothesis in which the loss of GUCY2C signaling in 
IBD changes the quantity, balance, and quality of stem 
cells which, in turn, contributes to their vulnerability to 
injury and attenuates regenerative responses restoring 
the damaged epithelium. These considerations suggest 
previously unanticipated pathophysiological paradigms 
underlying colorectal cancer and IBD which can be 
explored in future studies.
Beyond pathophysiology, these observations suggest 
correlative translational opportunities to develop novel 
therapeutic and preventive approaches that target ISCs. 
In that context, there are several oral GUCY2C ligands 
approved, or in development, to treat chronic constipation 
syndromes [57]. Lumenal expression of GUCY2C by stem 
cells highlights the feasibility of targeting this receptor 
using oral replacement strategies to correct paracrine 
hormone insufficiencies creating dysfunction in the 
ISC compartment. Indeed, here the FDA-approved oral 
GUCY2C ligand linaclotide (Linzess™) amplified the 
enteroid-forming capacity, a measure of stem cell quantity 
and quality, in wild type mice (see Figure 2H). Further, 
lumenal GUCY2C ligand replacement attenuates intestinal 
tumorigenesis in mice, and oral GUCY2C ligands are 
being examined as a novel chemoprevention strategy for 
colorectal cancer in humans [52, 58, 59]. Additionally, 
lumenal replacement of GUCY2C ligands ameliorates 
inflammation in mice, and these agents are in early 
clinical development in IBD patients [21, 60]. Moreover, 
the present study reveals that silencing the GUCY2C 
axis exacerbates the radiation-induced gastrointestinal 
syndrome (RIGS), the pathophysiology of which has been 
largely attributed to damage and death of ISCs [61, 62]. The 
present observations underscore the potential for therapeutic 
targeting of this signaling axis using oral GUCY2C ligands 
to defend the crypt to attenuate or prevent RIGS.
In conclusion, we demonstrate that the guanylate 
cyclase C (GUCY2C) paracrine signaling axis, a key 
regulator of intestinal epithelial homeostasis, maintains the 
integrity and balance of active and reserve intestinal stem 
cells by modulating endoplasmic reticulum stress. These 
studies reveal a novel role for GUCY2C in supporting 
intestinal stem cells. Importantly, they underscore the 
therapeutic potential of oral GUCY2C ligands to prevent 
or treat diseases reflecting intestinal stem cell dysfunction, 
including the radiation-induced gastrointestinal syndrome.
MATERIALS AND METHODS
Mice and treatments
Gucyc–/– (Gucy2ctm1Gar [63]), Lgr5-EGFP-
CreERT2 (B6.129P2-Lgr5tm1(cre/ERT2)Cle/J; Jax, Bar Harbor, 
ME, #008875) and Rosa-STOPfl-LacZ (B6.129S4-
Gt(ROSA)26Sortm1Sor/J; Jax #003474) transgenic mouse 
lines were interbred to generate offspring with the desired 
alleles. All mice were co-housed and Gucy2c+/+ (wild 
type) littermates with the appropriate alleles were used as 
controls. Tissues were harvested from adult mice (12-16 
wk of age). Cre was induced with a single 200 μL dose 
of tamoxifen (Sigma; Billerica, MA; T5648) in sunflower 
oil at 10 mg/ml. Tauroursodeoxycholic Acid (TUDCA, 
Millipore 580549) treatments were administered daily for 
3 d at 100 mg/kg/day intraperitoneally. Mice were exposed 
to a single 10 Gy dose of whole-body γ-irradiation with a 
PanTak, 310 kVe x-ray machine and tissues were harvested 
at noted time points after irradiation. In some experiments, 
mice were gavaged daily for 7 d with 100 μL of 20 mM 
8-cpt-cGMP. Each point in a graph (n) represents one 
mouse unless otherwise noted. All animal protocols were 
approved by the Thomas Jefferson University Institutional 
Animal Care and Use committee.
Immunohistochemistry and immunofluorescence
Intestines were harvested from mice, fixed in 
formalin, and embedded in paraffin as previously 
described [20]. Sections (4 μM) were cut then rehydrated 
in a sequential ethanol-to-water bath and stained with 
hematoxylin and eosin or antigen-specific primary 
and secondary antibodies. Primary antibodies for 
immunofluorescence included: anti-GFP, anti-Bmi1, and 
anti-GRP78 (Abcam; Cambridge, MA); anti-phospho 
VASP Ser239 (Sigma; Billerica, MA); and anti-GUCY2C 
(prepared and validated in-house) [64]. Secondary 
antibodies were from Life Technologies (Waltham, 
MA) and specific to the primary hosts. Tyramide signal 
amplification [65] was used to detect GUCY2C; secondary 
antibodies conjugated to horseradish peroxidase were from 
Jackson Immunoresearch Laboratories (cat #115-035-
206 and #111-036-046, 1:1000 dilution), and fluorescein-
conjugated tyramine was prepared from tyramine HCl 
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(cat #T2879, Sigma) and NHS-fluorescein (cat #46410, 
Thermo Scientific) as described [66]. For visualization of 
Rosa-LacZ lineage tracing, tamoxifen-induced recombinant 
Cre intestines were prepared as described previously [67]. 
At least 4 intestinal circumference sections were evaluated 
per mouse.
Crypt isolation and culture
Crypt isolation for subsequent analyses (enteroid 
assay, florescence-activated cell sorting (FACS), 
immunoblot) was performed using a variation of the 
chelation dissociation method [68]. Briefly, intestines 
were harvested, villi were gently scraped off for the 
small intestine, and tissues were minced and incubated 
in a 10 mM EDTA/Ca-free, Mg-free Hank’s Balanced 
Salt Solution (HBSS) on ice for a total of 40 min. 
Throughout this time, solutions were intermittently 
shaken by hand at the speed of two shakes/second, 
supernatant was disposed a total of six times, and fresh 
EDTA/HBSS was added after each disposal. Tissue 
was incubated undisturbed for 30 min on ice followed 
by vigorous pipetting with a 10 mL pipet to dissociate 
the remaining crypts. Crypts were filtered through a 
70 µM strainer and pelleted. For enteroid culture, the 
same number of crypts for each genotype (ranging from 
300–1500 crypts/well) were resuspended in a matrigel 
droplet (BD, 354230), pipetted briefly with a 1000 
μL micropipette, plated in 30 μL, and overlaid with 
350 μL of Intesticult media (Stem Cell Technologies, 
Vancouver, Canada; 06005). For FACS, crypts were 
incubated in 0.25% trypsin (Thermo Scientific, 
Philadelphia, PA; 15050065) at 37°C until a single cell 
suspension was obtained (not more than 10 min). Cells 
were then filtered a second time using a 40 µM strainer 
and kept in EDTA solution for sorting. 
Fluorescence-activated cell sorting
Cell populations from Lgr5-EGFP-CreERT2 mice 
were collected using a Coulter MoFlo Cell Sorter or 
analyzed using a BD LSRII. Live cells, determined by 
forward scatter, side scatter, and propidium iodide (PI, 
Roche), were gated negatively on CD45 (BD Pharmingen, 
San Jose, CA), then positively gated on CD24Low (BD 
Pharmingen) [69, 70]. Finally, cells were gated negatively 
(for differentiated cells) and positively (for Lgr5+ cells) 
gated on endogenous eGFP fluorescence (Supplementary 
Figure 1). 
Quantitative reverse transcriptase-polymerase 
chain reaction (RT-qPCR)
RNA from sorted cells was amplified and reverse 
transcribed in situ using total RNA from the CD45–/
CD24Low/EGFP+ population. RNA was amplified using 
MessageBOOSTER cDNA Synthesis Kit for qPCR 
(Epicentre, Madison, WI) and then subjected to one-step 
reverse transcription polymerase chain reaction using 
TaqMan EZ reverse-transcription polymerase chain 
reaction Core Reagents and appropriate primer/probes for 
TaqMan GeneExpression Assays in an ABI 7900 (Applied 
Biosystems, Norwalk, CT).
Immunoblot
Protein was extracted as described [52], quantitated 
using BCA assay (Pierce) and subjected to immunoblot 
analysis using anti-Bmi1 (Abcam; Cambridge, MA), anti-
CHOP, anti-calreticulin, anti-phospho-EIF2α, anti-β-tubulin 
(Cell Signaling, Danvers, MA) and anti-Grp78 (Abcam). 
Secondary antibodies were from Santa Cruz Biotechnology 
(Dallas, TX). Molecular weight markers (Cat. # 10748010, 
5 µL per run, or Cat. #LC5800, 10 µL per run) for 
immunoblot analyses were from Invitrogen (Grand 
Island, NY).
Transmission electron microscopy
Pieces (3 cm) of intestinal tissue were placed in 
fixative containing 2.5% glutaraldehyde, 0.1% tannic 
acid, and 0.1 mol/L phosphate buffer for 5 min three times 
and stored at 4°C. Tissues were mounted in plastic blocks, 
processed through 0.1 mol/L phosphate buffer supplied 
with 2% OsO4 (Osmium), uranyl acetate, then dehydrated 
through a graded acetone sequence. After being embedded 
in Spurrs media, blocks were sectioned and visualized 
using a FEI Tecnai 12 microscope and images will be 
captured with an AMT digital camera. Representative 
electron micrographs of each group were taken (kindly 
performed by Timothy Schneider, Department of 
Pathology, Thomas Jefferson University). Cells from at 
least 30 crypts were enumerated per mouse.
Statistical analyses
All analyses were conducted in a blinded fashion. 
Two-tailed student’s t-tests were used for single 
comparisons, and two-way analysis of variance (ANOVA) 
for multiple comparisons, unless otherwise indicated. 
Cohort sizes were calculated to be sufficient to detect 
two-tailed statistically significant differences with 95% 
confidence and 80% power, assuming unequal variances 
and allowing for unequal sample sizes between groups. 
P < 0.05 was considered significant. Statistical analyses 
were performed with GraphPad Prism 6 software. Data 
represent mean ± SEM.
Abbreviations
CBC, crypt base columnar; cGMP, cyclic GMP; ER, 
endoplasmic reticulum; GUCY2C, guanylyl cyclase C; 
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